The Anti-Cancer Multikinase Inhibitor Sorafenib Impairs Cardiac Contractility by Reducing Phospholamban Phosphorylation and Sarcoplasmic Calcium Transients

Tyrosine-kinase inhibitors (TKIs) have revolutionized cancer therapy in recent years. Although more targeted than conventional chemotherapy, TKIs exhibit substantial cardiotoxicity, often manifesting as hypertension or heart failure. Here, we assessed myocyte intrinsic cardiotoxic effects of the TKI...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Sci Rep
Autores principales: Schneider, Christopher, Wallner, Markus, Kolesnik, Ewald, Herbst, Viktoria, Mächler, Heinrich, Pichler, Martin, von Lewinski, Dirk, Sedej, Simon, Rainer, Peter P.
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5871797/
https://ncbi.nlm.nih.gov/pubmed/29593308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-018-23630-w
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares